
Opinion|Videos|May 7, 2025
MOMENTUM Trial Outcomes: Guiding Therapy for Myelofibrosis With Anemia and Splenomegaly
Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end point), meaningful spleen volume reduction (SVR25/SVR35), and anemia benefits, with experts noting that the inclusion of a washout period provided clearer evidence of momelotinib’s efficacy profile compared to the SIMPLIFY-2 trial.
Advertisement
Episodes in this series

Summary of MOMENTUM Trial: Momelotinib in Anemic, Symptomatic Myelofibrosis
Study Design and Population
- Patient characteristics:
- Required hemoglobin <10 g/dL
- Symptomatic disease
- Previously treated with Janus kinase (JAK) inhibitor therapy
- Design elements:
- Primary end point was symptom-driven
- Active comparator arm (danazol) rather than placebo
- Included a washout period (unlike SIMPLIFY-2)
Key Findings
- Primary end point:
- Momelotinib demonstrated superior symptom benefits compared to danazol
- Secondary end points:
- Multiple secondary end points met with superiority
- Stronger spleen volume reduction data (SVR25, SVR35) than in SIMPLIFY-2
- Confirmed anemia benefits
Clinical Implications
- Comprehensive benefit profile:
- Triple benefit: spleen reduction, symptom improvement, and anemia benefits
- Washout period may have contributed to clearer demonstration of spleen benefits compared to SIMPLIFY-2
- Clinician perspective:
- Some practitioners noted less direct relevance of danazol comparison in their practice
- Nevertheless, provided further evidence of momelotinib’s anemia benefit
- Results support momelotinib use in patients with anemic, symptomatic myelofibrosis who have received prior JAK inhibitor therapy
The MOMENTUM trial reinforces momelotinib’s position in the treatment algorithm, particularly for patients with anemia who have been previously treated with other JAK inhibitors.
Advertisement
Related to this article

Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).

Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5

